Recent publications published by researchers at the MRC WIMM.
Perturbing LSD1 and WNT rewires transcription to synergistically induce AML differentiation.
Hosseini A. et al, (2025), Nature
INCA033989: the first shot on goal for MPNs?
Benlabiod C. and Psaila B., (2024), Blood, 144, 2278 - 2279
When, which and how to switch: Navigating JAK inhibitors in myelofibrosis
O'Sullivan J. et al, (2024), British Journal of Haematology
A proinflammatory stem cell niche drives myelofibrosis through a targetable galectin-1 axis.
Li R. et al, (2024), Sci Transl Med, 16
Generating human bone marrow organoids for disease modeling and drug discovery.
Olijnik A-A. et al, (2024), Nat Protoc, 19, 2117 - 2146
Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib.
Rampotas A. et al, (2024), Blood, 143, 178 - 182
Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline.
McLornan DP. et al, (2024), Br J Haematol, 204, 127 - 135
Real World Efficacy and Safety of Momelotinib for Myelofibrosis: Evaluation of a UK-Wide Study Confirms 40% Anaemia Response Rate in a Non-Clinical Trial Cohort
Rampotas A. et al, (2024), BLOOD, 144, 1804 - 1806
RUX-AZA Response in AP/BP-MPN Is Driven By Release of the Differentiation Block in Mutant HSPCs: A Single-Cell Multi-Omic Analysis of Responders on the Phase Ib Phazar Study
Brierley CK. et al, (2024), BLOOD, 144, 3146 - 3147
The management of myelofibrosis: A British Society for Haematology Guideline.
McLornan DP. et al, (2024), Br J Haematol, 204, 136 - 150
Chromothripsis orchestrates leukemic transformation in blast phase MPN through targetable amplification of DYRK1A.
Brierley CK. et al, (2023), bioRxiv
Cooperation between SF3B1 and JAK2V617F Mutations Accelerates Fibrotic Progression in Myeloproliferative Neoplasms By Enhancing STAT1 Signaling
O Sullivan J. et al, (2023), Blood, 142, 861 - 861
Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution.
Rodriguez-Meira A. et al, (2023), Nat Genet, 55, 1531 - 1541
CNL and aCML should be considered as a single entity based on molecular profiles and outcomes.
Carreño-Tarragona G. et al, (2023), Blood Adv, 7, 1672 - 1681